---
title: "Real-World Safety of Nirmatrelvir Plus Ritonavir for COVID-19 in Japan: Post-Marketing Surveillance"
id: "pubmed-41621946"
canonical_url: "https://medichelpline.com/clinical-feed/pubmed-41621946"
content_type: "clinical_feed_article"
specialty: "Pharmacology"
source_name: "PubMed / NCBI"
source_url: "https://pubmed.ncbi.nlm.nih.gov/41621946/"
doi: "10.7883/yoken.JJID.2024.380"
published_at: "2026-11-19T00:00:00.000Z"
evidence_level: "Journal Article"
license: "CC-BY-NC-4.0 / Informational Use"
---
# Real-World Safety of Nirmatrelvir Plus Ritonavir for COVID-19 in Japan: Post-Marketing Surveillance
## Provenance & Clinical Metadata
- **Canonical URL:** https://medichelpline.com/clinical-feed/pubmed-41621946
- **Specialty:** [Pharmacology](https://medichelpline.com/clinical-feed/pharmacology.md)
- **Primary Source:** PubMed / NCBI
- **Source URL:** [Original Journal Publication](https://pubmed.ncbi.nlm.nih.gov/41621946/)
- **DOI:** [10.7883/yoken.JJID.2024.380](https://doi.org/10.7883%2Fyoken.JJID.2024.380)
- **Published At:** 2026-11-19T00:00:00.000Z
- **Evidence Rating:** Journal Article
## Executive GIST (TL;DR)
- Large-scale post-marketing surveillance collected safety data from 163 sites in Japan between February 2022 and May 2023. The safety analysis set included 2,829 patients. - The cohort had a mean age of 63.1 years (SD 18.0). Most infections were classified as **mild COVID-19** (80.8%); 97.3% had ≥1 risk factor for progression to severe disease. - Observation spanned from the first dose to 28 days after the last dose; median follow-up durations were not specified in the abstract. - Adverse drug reactions (ADRs) occurred in 15.0% (423 patients). The most frequent events were **dysgeusia** (6.7%), diarrhea (2.6%), taste disturbance (1.5%), nausea (1.2%), vomiting (0.5%), decreased appetite (0.5%), and rash (0.5%). - Median time to onset of common ADRs was 1–2 days; median recovery times ranged from 2 to 6 days for these events. - Serious ADRs were uncommon: six patients (0.2%) experienced serious events. Investigators reported no new safety signals in the surveillance period. - The most common reason for discontinuing follow-up was symptom improvement (17.1%); the abstract did not provide granular reasons for other discontinuations or details on loss to follow-up. - The source did not report dosing regimens, specific concomitant medications, detailed comorbidity breakdowns, or subgroup safety analyses; those methodological details were not included in the abstract. - Data indicated that the combination of **nirmatrelvir plus ritonavir** was generally well tolerated in this Japanese real-world population, with predictable, mostly transient ADRs.
## Clinical Analysis & Structured Key Points
Clipboard, Search History, and several other advanced features are temporarily unavailable. [ Skip to main page content ](https://pubmed.ncbi.nlm.nih.gov/41621946/#article-details) ### NIH Websites Are Changing * [Get the Latest Updates and FAQs on the transition](https://www.nih.gov/web-modernization) * Per [Executive Order 14434](https://www.whitehouse.gov/presidential-actions/2026/09/inaugurating-the-era-of-super-intelligence/), federal agencies are now using "Super Intelligence" (SI) in place of "Artificial Intelligence" (AI). You may see both terms across NIH content during this transition. ![U.S. flag](https://cdn.ncbi.nlm.nih.gov/coreutils/uswds/img/favicons/favicon-57.png) An official website of the United States government Here's how you know ![Dot gov](https://cdn.ncbi.nlm.nih.gov/coreutils/uswds/img/icon-dot-gov.svg) **The .gov means it’s official.** Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site. ![Https](https://cdn.ncbi.nlm.nih.gov/coreutils/uswds/img/icon-https.svg) **The site is secure.** The **https://** ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely. [ ![NIH NLM Logo](https://cdn.ncbi.nlm.nih.gov/coreutils/nwds/img/logos/AgencyLogo.svg) ](https://www.ncbi.nlm.nih.gov/) [Log in](https://account.ncbi.nlm.nih.gov/?back_url=https%3A%2F%2Fpubmed.ncbi.nlm.nih.gov%2F41621946%2F) Show account info Close #### Account Logged in as: **username** * [Dashboard](https://www.ncbi.nlm.nih.gov/myncbi/) * [Publications](https://www.ncbi.nlm.nih.gov/myncbi/collections/bibliography/) * [Account settings](https://www.ncbi.nlm.nih.gov/account/settings/) * [Log out](https://www.ncbi.nlm.nih.gov/account/signout/?back_url=https%3A//pubmed.ncbi.nlm.nih.gov/41621946/) [Access keys](https://www.ncbi.nlm.nih.gov/guide/browsers/#ncbi_accesskeys) [NCBI Homepage](https://www.ncbi.nlm.nih.gov) [MyNCBI Homepage](https://pubmed.ncbi.nlm.nih.gov/myncbi/) [Main Content](https://pubmed.ncbi.nlm.nih.gov/41621946/#maincontent) [Main Navigation](https://pubmed.ncbi.nlm.nih.gov/41621946/) [ ![pubmed logo](https://cdn.ncbi.nlm.nih.gov/pubmed/a447896c-976f-490b-b86b-2668b65114a8/core/images/pubmed-logo-blue.svg) ](https://pubmed.ncbi.nlm.nih.gov/) [ ](https://pubmed.ncbi.nlm.nih.gov/41621946/ "Show search bar") Search: [](https://pubmed.ncbi.nlm.nih.gov/41621946/ "Clear search input")Search [Advanced](https://pubmed.ncbi.nlm.nih.gov/advanced/) [ Clipboard ](https://pubmed.ncbi.nlm.nih.gov/clipboard/) [ User Guide ](https://pubmed.ncbi.nlm.nih.gov/help/) Save Email Send to * [ Clipboard ](https://pubmed.ncbi.nlm.nih.gov/41621946/) * [My Bibliography](https://account.ncbi.nlm.nih.gov/?back_url=https%3A%2F%2Fpubmed.ncbi.nlm.nih.gov%2F41621946%2F%23open-bibliography-panel) * [Collections](https://account.ncbi.nlm.nih.gov/?back_url=https%3A%2F%2Fpubmed.ncbi.nlm.nih.gov%2F41621946%2F%23open-collections-panel) * [Citation manager](https://pubmed.ncbi.nlm.nih.gov/41621946/) Display options Display options Format Abstract PubMed PMID ## Save citation to file Format: Summary (text) PubMed PMID Abstract (text) CSV Create file Cancel ## Email citation Email address has not been verified. Go to [ My NCBI account settings ](https://account.ncbi.nlm.nih.gov/settings/) to confirm your email and then refresh this page. To: Subject: Body: Format: Summary Summary (text) Abstract Abstract (text) MeSH and other data Send email Cancel ### Add to Collections * Create a new collection * Add to an existing collection Name your collection: Name must be less than 100 characters Choose a collection: Unable to load your collection due to an error [Please try again](https://pubmed.ncbi.nlm.nih.gov/41621946/) Add Cancel ### Add to My Bibliography * My Bibliography Unable to load your delegates due to an error [Please try again](https://pubmed.ncbi.nlm.nih.gov/41621946/) Add Cancel ## Your saved search Name of saved search: Search terms: [Test search terms](https://pubmed.ncbi.nlm.nih.gov/41621946/) Would you like email updates of new search results? Saved Search Alert Radio Buttons * Yes * No Email: ([change](https://www.ncbi.nlm.nih.gov/account/settings/)) Frequency: Monthly Weekly Daily Which day? The first Sunday The first Monday The first Tuesday The first Wednesday The first Thursday The first Friday The first Saturday The first day The first weekday Which day? Sunday Monday Tuesday Wednesday Thursday Friday Saturday Report format: Summary Summary (text) Abstract Abstract (text) PubMed Send at most: 1 item 5 items 10 items 20 items 50 items 100 items 200 items Send even when there aren't any new results Optional text in email: Save Cancel ## Create a file for external citation management software Create file Cancel ## Your RSS Feed Name of RSS Feed: Number of items displayed: 5 10 15 20 50 100 Create RSS Cancel RSS Link Copy ### Full text links [![J-STAGE, Japan Science and Technology Information Aggregator, Electronic full text link](https://cdn.ncbi.nlm.nih.gov/corehtml/query/egifs/https:--www.jstage.jst.go.jp-pub-images-pubmed-logo.gif) J-STAGE, Japan Science and Technology Information Aggregator, Electronic ](https://dx.doi.org/10.7883/yoken.JJID.2024.380 "See full text options at J-STAGE, Japan Science and Technology Information Aggregator, Electronic") [ Full text links ](https://pubmed.ncbi.nlm.nih.gov/41621946/) ### Actions Cite Collections Add to Collections * Create a new collection * Add to an existing collection Name your collection: Name must be less than 100 characters Choose a collection: Unable to load your collection due to an error [Please try again](https://pubmed.ncbi.nlm.nih.gov/41621946/) Add Cancel Permalink Permalink Copy Display options Display options Format Abstract PubMed PMID ### Experimental Resource Linked Discoveries ### Page navigation * [ Title & authors ](https://pubmed.ncbi.nlm.nih.gov/41621946/#heading) * [ Abstract ](https://pubmed.ncbi.nlm.nih.gov/41621946/#abstract) * [Similar articles](https://pubmed.ncbi.nlm.nih.gov/41621946/#similar) * [ MeSH terms ](https://pubmed.ncbi.nlm.nih.gov/41621946/#mesh-terms) * [ Substances ](https://pubmed.ncbi.nlm.nih.gov/41621946/#substances) * [Related information](https://pubmed.ncbi.nlm.nih.gov/41621946/#related-links) * [ LinkOut - more resources ](https://pubmed.ncbi.nlm.nih.gov/41621946/#linkout) Title & authors Abstract Similar articles MeSH terms Substances Related information LinkOut - more resources Jpn J Infect Dis Actions * [ Search in PubMed ](https://pubmed.ncbi.nlm.nih.gov/?term=%22Jpn+J+Infect+Dis%22%5Bjour%5D&sort=date&sort_order=desc) * [ Search in NLM Catalog ](https://www.ncbi.nlm.nih.gov/nlmcatalog?term=%22Jpn+J+Infect+Dis%22%5BTitle+Abbreviation%5D) * [ Add to Search ](https://pubmed.ncbi.nlm.nih.gov/41621946/) . 2026 Nov 19;79(6):236-246. doi: 10.7883/yoken.JJID.2024.380. Epub 2026 Jan 30. # Real-World Safety of Nirmatrelvir Plus Ritonavir in Patients with COVID-19 in Japan: A Post-Marketing Surveillance Study [Koichi Murata](https://pubmed.ncbi.nlm.nih.gov/?term=Murata+K&cauthor_id=41621946)[ 1 ](https://pubmed.ncbi.nlm.nih.gov/41621946/#full-view-affiliation-1 "Medical Affairs, Pfizer Japan Inc., Japan."), [Sachiko Hyokai](https://pubmed.ncbi.nlm.nih.gov/?term=Hyokai+S&cauthor_id=41621946)[ 1 ](https://pubmed.ncbi.nlm.nih.gov/41621946/#full-view-affiliation-1 "Medical Affairs, Pfizer Japan Inc., Japan."), [Yosuke Fujii](https://pubmed.ncbi.nlm.nih.gov/?term=Fujii+Y&cauthor_id=41621946)[ 2 ](https://pubmed.ncbi.nlm.nih.gov/41621946/#full-view-affiliation-2 "Biometrics & Data Management, Pfizer R&D Japan G.K., Japan."), [Mika Morimasa](https://pubmed.ncbi.nlm.nih.gov/?term=Morimasa+M&cauthor_id=41621946)[ 3 ](https://pubmed.ncbi.nlm.nih.gov/41621946/#full-view-affiliation-3 "PMS Affairs, Pfizer R&D Japan G.K., Japan.") Affiliations Expand ### Affiliations * 1 Medical Affairs, Pfizer Japan Inc., Japan. * 2 Biometrics & Data Management, Pfizer R&D Japan G.K., Japan. * 3 PMS Affairs, Pfizer R&D Japan G.K., Japan. * PMID: **41621946** * DOI: [ 10.7883/yoken.JJID.2024.380 ](https://doi.org/10.7883/yoken.jjid.2024.380) Free article Item in Clipboard # Real-World Safety of Nirmatrelvir Plus Ritonavir in Patients with COVID-19 in Japan: A Post-Marketing Surveillance Study Koichi Murata et al. Jpn J Infect Dis. 2026. Free article Show details Display options Display options Format Abstract PubMed PMID Jpn J Infect Dis Actions * [ Search in PubMed ](https://pubmed.ncbi.nlm.nih.gov/?term=%22Jpn+J+Infect+Dis%22%5Bjour%5D&sort=date&sort_order=desc) * [ Search in NLM Catalog ](https://www.ncbi.nlm.nih.gov/nlmcatalog?term=%22Jpn+J+Infect+Dis%22%5BTitle+Abbreviation%5D) * [ Add to Search ](https://pubmed.ncbi.nlm.nih.gov/41621946/) . 2026 Nov 19;79(6):236-246. doi: 10.7883/yoken.JJID.2024.380. Epub 2026 Jan 30. ### Authors [Koichi Murata](https://pubmed.ncbi.nlm.nih.gov/?term=Murata+K&cauthor_id=41621946)[ 1 ](https://pubmed.ncbi.nlm.nih.gov/41621946/#short-view-affiliation-1 "Medical Affairs, Pfizer Japan Inc., Japan."), [Sachiko Hyokai](https://pubmed.ncbi.nlm.nih.gov/?term=Hyokai+S&cauthor_id=41621946)[ 1 ](https://pubmed.ncbi.nlm.nih.gov/41621946/#short-view-affiliation-1 "Medical Affairs, Pfizer Japan Inc., Japan."), [Yosuke Fujii](https://pubmed.ncbi.nlm.nih.gov/?term=Fujii+Y&cauthor_id=41621946)[ 2 ](https://pubmed.ncbi.nlm.nih.gov/41621946/#short-view-affiliation-2 "Biometrics & Data Management, Pfizer R&D Japan G.K., Japan."), [Mika Morimasa](https://pubmed.ncbi.nlm.nih.gov/?term=Morimasa+M&cauthor_id=41621946)[ 3 ](https://pubmed.ncbi.nlm.nih.gov/41621946/#short-view-affiliation-3 "PMS Affairs, Pfizer R&D Japan G.K., Japan.") ### Affiliations * 1 Medical Affairs, Pfizer Japan Inc., Japan. * 2 Biometrics & Data Management, Pfizer R&D Japan G.K., Japan. * 3 PMS Affairs, Pfizer R&D Japan G.K., Japan. * PMID: **41621946** * DOI: [ 10.7883/yoken.JJID.2024.380 ](https://doi.org/10.7883/yoken.jjid.2024.380) Item in Clipboard Full text links Cite Display options Display options Format Abstract PubMed PMID Linked Discoveries ## Abstract This large-scale post-marketing surveillance study (163 sites; February 2022-May 2023) evaluated the real-world safety and effectiveness of a newly initiated nirmatrelvir plus ritonavir combination for patients with COVID-19 in Japan. The current study presents a safety evaluation. The observation period was from the first day of administration to 28 days after the last day. The safety analysis set comprised 2829 patients (mean [standard deviation] age, 63.1 [18.0] years; mild COVID-19, 80.8%; ≥1 risk factor for progression to severe COVID-19, 97.3%). The most common reason for discontinuing follow-up was symptom improvement (17.1%). Adverse drug reactions (ADRs) were observed in 423 (15.0%) patients (incidence [%]): dysgeusia (6.7%), diarrhea (2.6%), taste disturbance (1.5%), nausea (1.2%), vomiting (0.5%), decreased appetite (0.5%), and rash (0.5%). The median times to onset and recovery of these ADRs were 1-2 days and 2-6 days, respectively. Serious ADRs were observed in six patients (0.2%). No new safety signals were observed. The study showed that nirmatrelvir plus ritonavir was well tolerated in Japanese patients with COVID-19 in a real-world clinical setting. **Keywords:** COVID-19; Japan; nirmatrelvir plus ritonavir; real-world; safety. [PubMed Disclaimer](https://pubmed.ncbi.nlm.nih.gov/disclaimer/) ## Similar articles * [ Nirmatrelvir combined with ritonavir for preventing and treating COVID-19. ](https://pubmed.ncbi.nlm.nih.gov/36126225/) Reis S, Metzendorf MI, Kuehn R, Popp M, Gagyor I, Kranke P, Meybohm P, Skoetz N, Weibel S.Reis S, et al.Cochrane Database Syst Rev. 2022 Sep 20;9(9):CD015395. doi: 10.1002/14651858.CD015395.pub2.Cochrane Database Syst Rev. 2022.Update in: [Cochrane Database Syst Rev. 2023 Nov 30;11:CD015395. doi: 10.1002/14651858.CD015395.pub3.](https://pubmed.ncbi.nlm.nih.gov/38032024/)PMID: 36126225Free PMC article.Updated. * [ Investigating the Safety Profile of Fast-Track COVID-19 Drugs Using the FDA Adverse Event Reporting System Database: A Comparative Observational Study. ](https://pubmed.ncbi.nlm.nih.gov/39533148/) Kim HJ, Yoon JH, Lee KH.Kim HJ, et al.Pharmacoepidemiol Drug Saf. 2024 Nov;33(11):e70043. doi: 10.1002/pds.70043.Pharmacoepidemiol Drug Saf. 2024.PMID: 39533148 * [ Nirmatrelvir combined with ritonavir for preventing and treating COVID-19. ](https://pubmed.ncbi.nlm.nih.gov/38032024/) Reis S, Metzendorf MI, Kuehn R, Popp M, Gagyor I, Kranke P, Meybohm P, Skoetz N, Weibel S.Reis S, et al.Cochrane Database Syst Rev. 2023 Nov 30;11(11):CD015395. doi: 10.1002/14651858.CD015395.pub3.Cochrane Database Syst Rev. 2023.PMID: 38032024Free PMC article. * [ Oral Nirmatrelvir for High-Risk, Nonhospitalized Adults with Covid-19. ](https://pubmed.ncbi.nlm.nih.gov/35172054/) Hammond J, Leister-Tebbe H, Gardner A, Abreu P, Bao W, Wisemandle W, Baniecki M, Hendrick VM, Damle B, Simón-Campos A, Pypstra R, Rusnak JM; EPIC-HR Investigators.Hammond J, et al.N Engl J Med. 2022 Apr 14;386(15):1397-1408. doi: 10.1056/NEJMoa2118542. Epub 2022 Feb 16.N Engl J Med. 2022.PMID: 35172054Free PMC article.Clinical Trial. * [ The Durable Safety and Effectiveness of Lixisenatide in Japanese People with Type 2 Diabetes: The Post-Marketing Surveillance PRANDIAL Study. ](https://pubmed.ncbi.nlm.nih.gov/35449321/) Terauchi Y, Usami M, Inoue T.Terauchi Y, et al.Adv Ther. 2022 Jun;39(6):2873-2888. doi: 10.1007/s12325-022-02121-5. Epub 2022 Apr 21.Adv Ther. 2022.PMID: 35449321Free PMC article. [ See all similar articles ](https://pubmed.ncbi.nlm.nih.gov/?linkname=pubmed_pubmed&from_uid=41621946) ## MeSH terms * Adult Actions * [ Search in PubMed ](https://pubmed.ncbi.nlm.nih.gov/?term=%22Adult%22%5BMeSH%5D&sort=date&sort_order=desc) * [ Search in MeSH ](https://www.ncbi.nlm.nih.gov/mesh?term=Adult) * [ Add to Search ](https://pubmed.ncbi.nlm.nih.gov/41621946/) * Aged Actions * [ Search in PubMed ](https://pubmed.ncbi.nlm.nih.gov/?term=%22Aged%22%5BMeSH%5D&sort=date&sort_order=desc) * [ Search in MeSH ](https://www.ncbi.nlm.nih.gov/mesh?term=Aged) * [ Add to Search ](https://pubmed.ncbi.nlm.nih.gov/41621946/) * Aged, 80 and over Actions * [ Search in PubMed ](https://pubmed.ncbi.nlm.nih.gov/?term=%22Aged%2C+80+and+over%22%5BMeSH%5D&sort=date&sort_order=desc) * [ Search in MeSH ](https://www.ncbi.nlm.nih.gov/mesh?term=Aged%2C+80+and+over) * [ Add to Search ](https://pubmed.ncbi.nlm.nih.gov/41621946/) * Antiviral Agents* / administration & dosage Actions * [ Search in PubMed ](https://pubmed.ncbi.nlm.nih.gov/?term=%22Antiviral+Agents%2Fadministration+and+dosage%22%5BMAJR%5D&sort=date&sort_order=desc) * [ Search in MeSH ](https://www.ncbi.nlm.nih.gov/mesh?term=Antiviral+Agents) * [ Add to Search ](https://pubmed.ncbi.nlm.nih.gov/41621946/) * Antiviral Agents* / adverse effects Actions * [ Search in PubMed ](https://pubmed.ncbi.nlm.nih.gov/?term=%22Antiviral+Agents%2Fadverse+effects%22%5BMAJR%5D&sort=date&sort_order=desc) * [ Search in MeSH ](https://www.ncbi.nlm.nih.gov/mesh?term=Antiviral+Agents) * [ Add to Search ](https://pubmed.ncbi.nlm.nih.gov/41621946/) * Antiviral Agents* / therapeutic use Actions * [ Search in PubMed ](https://pubmed.ncbi.nlm.nih.gov/?term=%22Antiviral+Agents%2Ftherapeutic+use%22%5BMAJR%5D&sort=date&sort_order=desc) * [ Search in MeSH ](https://www.ncbi.nlm.nih.gov/mesh?term=Antiviral+Agents) * [ Add to Search ](https://pubmed.ncbi.nlm.nih.gov/41621946/) * COVID-19 Actions * [ Search in PubMed ](https://pubmed.ncbi.nlm.nih.gov/?term=%22COVID-19%22%5BMeSH%5D&sort=date&sort_order=desc) * [ Search in MeSH ](https://www.ncbi.nlm.nih.gov/mesh?term=COVID-19) * [ Add to Search ](https://pubmed.ncbi.nlm.nih.gov/41621946/) * COVID-19 Drug Treatment* Actions * [ Search in PubMed ](https://pubmed.ncbi.nlm.nih.gov/?term=%22COVID-19+Drug+Treatment%22%5BMAJR%5D&sort=date&sort_order=desc) * [ Search in MeSH ](https://www.ncbi.nlm.nih.gov/mesh?term=COVID-19+Drug+Treatment) * [ Add to Search ](https://pubmed.ncbi.nlm.nih.gov/41621946/) * Drug Therapy, Combination Actions * [ Search in PubMed ](https://pubmed.ncbi.nlm.nih.gov/?term=%22Drug+Therapy%2C+Combination%22%5BMeSH%5D&sort=date&sort_order=desc) * [ Search in MeSH ](https://www.ncbi.nlm.nih.gov/mesh?term=Drug+Therapy%2C+Combination) * [ Add to Search ](https://pubmed.ncbi.nlm.nih.gov/41621946/) * Dysgeusia / chemically induced Actions * [ Search in PubMed ](https://pubmed.ncbi.nlm.nih.gov/?term=%22Dysgeusia%2Fchemically+induced%22%5BMeSH%5D&sort=date&sort_order=desc) * [ Search in MeSH ](https://www.ncbi.nlm.nih.gov/mesh?term=Dysgeusia) * [ Add to Search ](https://pubmed.ncbi.nlm.nih.gov/41621946/) * Female Actions * [ Search in PubMed ](https://pubmed.ncbi.nlm.nih.gov/?term=%22Female%22%5BMeSH%5D&sort=date&sort_order=desc) * [ Search in MeSH ](https://www.ncbi.nlm.nih.gov/mesh?term=Female) * [ Add to Search ](https://pubmed.ncbi.nlm.nih.gov/41621946/) * Humans Actions * [ Search in PubMed ](https://pubmed.ncbi.nlm.nih.gov/?term=%22Humans%22%5BMeSH%5D&sort=date&sort_order=desc) * [ Search in MeSH ](https://www.ncbi.nlm.nih.gov/mesh?term=Humans) * [ Add to Search ](https://pubmed.ncbi.nlm.nih.gov/41621946/) * Japan / epidemiology Actions * [ Search in PubMed ](https://pubmed.ncbi.nlm.nih.gov/?term=%22Japan%2Fepidemiology%22%5BMeSH%5D&sort=date&sort_order=desc) * [ Search in MeSH ](https://www.ncbi.nlm.nih.gov/mesh?term=Japan) * [ Add to Search ](https://pubmed.ncbi.nlm.nih.gov/41621946/) * Male Actions * [ Search in PubMed ](https://pubmed.ncbi.nlm.nih.gov/?term=%22Male%22%5BMeSH%5D&sort=date&sort_order=desc) * [ Search in MeSH ](https://www.ncbi.nlm.nih.gov/mesh?term=Male) * [ Add to Search ](https://pubmed.ncbi.nlm.nih.gov/41621946/) * Middle Aged Actions * [ Search in PubMed ](https://pubmed.ncbi.nlm.nih.gov/?term=%22Middle+Aged%22%5BMeSH%5D&sort=date&sort_order=desc) * [ Search in MeSH ](https://www.ncbi.nlm.nih.gov/mesh?term=Middle+Aged) * [ Add to Search ](https://pubmed.ncbi.nlm.nih.gov/41621946/) * Product Surveillance, Postmarketing Actions * [ Search in PubMed ](https://pubmed.ncbi.nlm.nih.gov/?term=%22Product+Surveillance%2C+Postmarketing%22%5BMeSH%5D&sort=date&sort_order=desc) * [ Search in MeSH ](https://www.ncbi.nlm.nih.gov/mesh?term=Product+Surveillance%2C+Postmarketing) * [ Add to Search ](https://pubmed.ncbi.nlm.nih.gov/41621946/) * Ritonavir* / administration & dosage Actions * [ Search in PubMed ](https://pubmed.ncbi.nlm.nih.gov/?term=%22Ritonavir%2Fadministration+and+dosage%22%5BMAJR%5D&sort=date&sort_order=desc) * [ Search in MeSH ](https://www.ncbi.nlm.nih.gov/mesh?term=Ritonavir) * [ Add to Search ](https://pubmed.ncbi.nlm.nih.gov/41621946/) * Ritonavir* / adverse effects Actions * [ Search in PubMed ](https://pubmed.ncbi.nlm.nih.gov/?term=%22Ritonavir%2Fadverse+effects%22%5BMAJR%5D&sort=date&sort_order=desc) * [ Search in MeSH ](https://www.ncbi.nlm.nih.gov/mesh?term=Ritonavir) * [ Add to Search ](https://pubmed.ncbi.nlm.nih.gov/41621946/) * Ritonavir* / therapeutic use Actions * [ Search in PubMed ](https://pubmed.ncbi.nlm.nih.gov/?term=%22Ritonavir%2Ftherapeutic+use%22%5BMAJR%5D&sort=date&sort_order=desc) * [ Search in MeSH ](https://www.ncbi.nlm.nih.gov/mesh?term=Ritonavir) * [ Add to Search ](https://pubmed.ncbi.nlm.nih.gov/41621946/) * SARS-CoV-2 Actions * [ Search in PubMed ](https://pubmed.ncbi.nlm.nih.gov/?term=%22SARS-CoV-2%22%5BMeSH%5D&sort=date&sort_order=desc)
## Related Clinical Research

- [Diabetes prevalence in NYC schoolchildren using the Automated Student Health Record](https://medichelpline.com/clinical-feed/pubmed-43013498.md) (DOI: 10.1371/journal.pone.0344345)
- [Novo and Medicare’s Bridge program: what STAT reported and what wasn’t disclosed](https://medichelpline.com/clinical-feed/stat-news-1-stat-novo-may-be-getting-a-better-deal-than-expected-with-medicare-s-bridge.md)
- [U.S. POINTER: Structured lifestyle program slows brain aging and cardiometabolic risk over 24 mont](https://medichelpline.com/clinical-feed/medical-news-today-0-combining-physical-mental-and-social-habits-slows-brain-aging-in-2-year-trial.md)
- [GLP-1 receptor agonist and prevention of post–COVID-19 pulmonary fibrosis in type 2 diabetes](https://medichelpline.com/clinical-feed/pubmed-42423377.md) (DOI: 10.1128/jvi.00401-26)
- [Sanofi Pompe drug shortages, Jazz Pharma buys Actio, and Lilly’s Foundayo OKed in U.K.](https://medichelpline.com/clinical-feed/stat-news-4-stat-pharmalittle-we-re-reading-about-a-sanofi-drug-shortage-a-jazz-pharma-deal.md)

## Navigation
- [← Back to Pharmacology Feed](https://medichelpline.com/clinical-feed/pharmacology.md)
- [← All Clinical Specialties](https://medichelpline.com/clinical-feed.md)
## Medical & Regulatory Disclaimer

> [!CAUTION]
> MedicHelpline content is structured for research, educational, and professional discovery purposes. It does not constitute individual medical advice, clinical diagnosis, or treatment recommendations.
> Always verify dosing, contraindications, and regulatory alerts against official product labeling and primary regulatory sources before clinical decision-making.